Healthcare
ALKS Stock Analysis
Alkermes plc · current price $47.44 (-2.95% today)
Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
ALKS Stock AnalysisAlkermes plc · current price $47.44 (-2.95% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading ALKS’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading ALKS’s filings…
| Quarter | EPS | Est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-30 | $0.65 | $0.39 | +68.5% | Beat |
| 2025-12-31 | $0.48 | $0.45 | +7.7% | Beat |
| 2026-03-31 | $0.38 | $-0.04 | +1053.0% | Beat |
| 2026-06-30 | $0.70 | $0.29 | +141.3% | Beat |
Alkermes plc (ALKS) currently has a TickerMover Quant Score of 55/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. ALKS scores 55/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
ALKS's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for ALKS →
